Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie om de veiligheid en effectiviteit van de InnAVasc arterioveneuze graft voor toegang tot hemodialyse te evalueren

5 november 2026 bijgewerkt door: W.L.Gore & Associates

Een studie ter evaluatie van de veiligheid en effectiviteit van de InnAVasc arterioveneuze graft voor toegang tot hemodialyse bij patiënten met nierziekte in het eindstadium

The goal of the CSP-2002 clinical trial is to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD). The primary study endpoints are:

Primary Effectiveness Endpoint: The proportion of subjects with secondary patency at 6 months.

Primary Safety Endpoint: The incidence of device-related adverse events of special interest (AESIs) through 6 months.

Participants will be asked to sign an informed consent form. Once enrolled, they will be assessed to receive the study graft implant and asked to participate in periodic follow-up visits and assessments through 2 years following implant.

Studie Overzicht

Gedetailleerde beschrijving

The InnAVasc Arteriovenous Graft (IG) is intended for use in ESRD hemodialysis (HD) patients who require HD and whose next most appropriate access is an arteriovenous graft (AVG), also including those who may require an immediate cannulation AVG.

Patients with ESRD who require HD and are suitable for an AVG for HD access will be eligible for inclusion in the study. Subjects will be implanted with an InnAVasc Arteriovenous Graft (IG) in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a "straight" (soft "C") configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop). Placing the graft across the elbow will be prohibited. Subjects must be able to be on antiplatelet therapy per the discretion of their physician (e.g., aspirin, clopidogrel, etc.).

Studietype

Ingrijpend

Inschrijving (Geschat)

133

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85012
        • AKDHC Medical Research Services, LLC
    • California
      • La Mesa, California, Verenigde Staten, 91942
        • Sharp Center for Research
    • Florida
      • Sarasota, Florida, Verenigde Staten, 34239
        • Sarasota Memorial Hospital
      • Tampa, Florida, Verenigde Staten, 33606
        • University of South Florida
    • Georgia
      • Augusta, Georgia, Verenigde Staten, 30901
        • Piedmont Augusta
    • Kentucky
      • Louisville, Kentucky, Verenigde Staten, 40202
        • University of Louisville
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21201
        • University of Maryland
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Brigham & Women's Hospital
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68118
        • Methodist Physicians Clinic
    • New Jersey
      • Newark, New Jersey, Verenigde Staten, 07103
        • Rutgers
    • New York
      • New York, New York, Verenigde Staten, 10029
        • Mount Sinai Hospital
      • New York, New York, Verenigde Staten, 10075
        • Northwell Health
      • The Bronx, New York, Verenigde Staten, 10467
        • Montefiore Medical Center
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28204
        • Surgical Specialists of Charlotte
      • Durham, North Carolina, Verenigde Staten, 27705
        • Duke University Medical Center
      • Raleigh, North Carolina, Verenigde Staten, 27607
        • NC Heart and Vascular Research, LLC
      • Raleigh, North Carolina, Verenigde Staten, 27610
        • WakeMed
    • Pennsylvania
      • Sayre, Pennsylvania, Verenigde Staten, 18840
        • Guthrie Clinic
    • South Carolina
      • Greenville, South Carolina, Verenigde Staten, 29615
        • Prisma Health- Upstate
      • Orangeburg, South Carolina, Verenigde Staten, 29118
        • Medical University of South Carolina
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Houston Methodist Hopsital
    • Washington
      • Seattle, Washington, Verenigde Staten, 98195
        • University of Washington

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 90 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Pre-Operative Inclusion Criteria:

Patients must meet the following criteria at screening in order to be scheduled for a procedure and potentially enrolled in the study:

  1. Patients with ESRD whose next most appropriate option for AV access is placement of an AV graft to start or maintain hemodialysis therapy;
  2. Age 18 to 90 years old, inclusive;
  3. Suitable anatomy for implantation of upper arm "straight" or looped graft, or forearm looped graft (graft not to cross the bend of the elbow);
  4. Ability to continue or commence antiplatelet therapy post graft implant (anticoagulation medication is acceptable if the subject is required to take an anticoagulant for a baseline medical condition);
  5. Able and willing to give informed consent;
  6. Anticipated life expectancy of at least 1 year.

Intra-Operative Inclusion Criteria:

Both vessels have been exposed and are deemed appropriate for implantation (i.e., based on the surgeon's opinion, artery is of adequate size, has adequate pulse to support AV access flow, is without significant calcification, and is safely clampable; and the vein is of adequate size, free of localized sclerosis, and is free of immediate outflow obstruction).

Pre-Operative Exclusion Criteria:

Patients will be excluded from the study at screening if they exhibit any of the following exclusion criteria:

  1. History or evidence of severe cardiac disease (i.e., debilitating heart failure, or high risk of MI) in the opinion of the investigator which may preclude participation in and completion of the study;
  2. Uncontrolled diabetes in the opinion of the investigator (i.e., multiple recent diabetes related hospitalizations);
  3. For upper arm straight configuration, an antecubital fossa crease to axillary crease distance < 18 cm;
  4. History or evidence of severe peripheral arterial disease in the extremity selected for implant (i.e., arterial inflow insufficient to support hemodialysis access);
  5. Known or suspected central vein stenosis or obstruction on the side of planned graft implantation;
  6. Baseline hypotension or history of frequent hypotensive episodes during dialysis that, in the opinion of the investigator, puts the patient at increased risk of graft thrombosis;
  7. Uncontrolled hypertension, per the opinion of the investigator (i.e., recent history of recurrent hospitalizations for hypertensive related illness);
  8. Baseline hemoglobin <7 g/dL;
  9. Baseline platelet count <50,000 or >500,000 cells/mm3;
  10. Documented history of stroke within 6 months prior to enrollment;
  11. Treatment with any investigational drug or device within 30 days prior to enrollment;
  12. Female patients who are pregnant, intending to become pregnant, nursing or intending to breastfeed during the study (pregnancy test may only be omitted, if patient is post-menopausal or has a documented history of hysterectomy or permanent sterilization);
  13. History of cancer with active disease or treatment within the previous year, except for non-invasive basal or squamous cell carcinoma of the skin;
  14. Immunodeficiency including documented history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) or patients receiving immunosuppressive therapy for treatment of an acute inflammatory event or autoimmune flare. Chronic immunosuppressive therapy is acceptable;
  15. Documented or suspected hypercoagulable condition;
  16. Bleeding diathesis, other than that associated with ESRD;
  17. Documented history of heparin-induced thrombocytopenia (HIT);
  18. Active local or systemic infection as documented from the medical history or bloodwork/blood culture data. If the infection resolves, the subject must be at least one-week post resolution of that infection before implantation;
  19. Scheduled renal transplant within 6 months;
  20. Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and effectiveness of the IG;
  21. Patient is unable or unwilling to complete all required follow-up assessments and questionnaires.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Experimental: InnAVasc AVG treatment

Patients will be surgically implanted with an InnAVasc Arteriovenous Graft (IG) in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a "straight" (soft "C") configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop).

The InnAVasc Arteriovenous Graft (IG) is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Secondary patency of study device at 6 months
Tijdsspanne: 6 months

The primary effectiveness endpoint is defined as the proportion of subjects with secondary patency at 6 months.

6 months
Incidence of adverse events of special interest related to InnAVasc AVG [Time Frame: through 6 months]
Tijdsspanne: 6 months

The primary safety endpoint is the incidence of device-related adverse events of special interest (AESIs) through 6 months, defined as:

  1. Infection of the study graft;
  2. Pseudoaneurysm formation at any point along the study graft requiring surgical or endovascular intervention (pseudoaneurysms that occur at sites of needle cannulation, but which are small enough to be observed without intervention, do not trigger this element of the AESI endpoint);
  3. Bleeding from the study graft requiring surgical or endovascular intervention or ≥2-unit blood transfusion;
  4. Hematoma from the study graft requiring surgical or endovascular intervention;
  5. Seroma of the study graft requiring surgical or endovascular intervention;
6 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Successful cannulation on or before Postoperative Day 7
Tijdsspanne: 7 days

Proportion of subjects achieving successful cannulation on or before Day 7, defined as the first 2-needle dialysis session through the study graft

7 days
Sustained use
Tijdsspanne: 3, 6, 12, 18 and 24 months

Proportion of subjects achieving sustained use of 3 months, 6, months, 12 months, 18 months and 24 months. Sustained use is a period of time in which the study graft is used for consecutive dialysis sessions without the requirement for alternative hemodialysis vascular access to be used as a route to receive renal replacement therapy. A sustained use period can be achieved at any time throughout the study period of 24 months.

3, 6, 12, 18 and 24 months

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Primary Patency Rate
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory endpoint 1: Time from creation of access to first intervention to maintain patency or thrombosis

3, 6, 12, 18 and 24 months
Assisted Primary Patency Rate
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory endpoint 2: Time from creation of access to first thrombosis, irrespective of intervention to maintain patency.

3, 6, 12, 18 and 24 months
Secondary Patency Rate
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory endpoint 3: Time from creation of access to study graft abandonment or achievement of a censored event (death, transfer to peritoneal dialysis, renal transplant, steal, venous hypertension, or end of study period), and includes all surgical and endovascular interventions to reestablish study graft patency.

3, 6, 12, 18 and 24 months
Thrombosis rate per patient
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory endpoint 4: The per patient rate of thrombosis events of the study graft at a particular timepoint.

3, 6, 12, 18 and 24 months
Proportion of subjects achieving successful cannulation among those for whom it was attempted on or before Day 7
Tijdsspanne: First use of study graft

Exploratory endpoint 5: Proportion of subjects achieving successful cannulation among those for whom it was attempted on or before Day 7, defined as the first 2-needle dialysis session through the study graft

First use of study graft
Days of central venous catheter insitu
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory endpoint 6: Cumulative catheter days insitu

3, 6, 12, 18 and 24 months
Incidence of individual adverse events
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory endpoint 7: cumulative adverse events, irrespective of device relatedness

3, 6, 12, 18 and 24 months
Change from baseline Patient Reported Outcomes Measures/Patient Reported Experience Measures (PROM/PREM) survey (SF-VAQ);
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory endpoint 8: Change of responses over time from baseline

3, 6, 12, 18 and 24 months
Intervention rate to restore or maintain patency
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory outcome 9: Intervention rate to restore or maintain patency (per patient per year)

3, 6, 12, 18 and 24 months
Health Economics data analysis
Tijdsspanne: 3, 6, 12, 18 and 24 months

Exploratory endpoint 10: Health Economic data analysis to be performed based on available study data for the for treatment related costs (e.g. procedural costs, hospital costs, etc.)

3, 6, 12, 18 and 24 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: John Ross, MD, MUSC Health Dialysis Access Institute

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

3 december 2020

Primaire voltooiing (Geschat)

1 maart 2030

Studie voltooiing (Geschat)

1 september 2031

Studieregistratiedata

Eerst ingediend

5 december 2020

Eerst ingediend dat voldeed aan de QC-criteria

11 december 2020

Eerst geplaatst (Werkelijk)

17 december 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren